| abstract |
3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid in form I ( A solid dispersion comprising compound 1) and substantially amorphous N- (5-hydroxy-2,4-ditert-butyl-phenyl) -4-oxo-1H-quinoline-3-carboxamide (compound 2) Disclosed are methods for preparing pharmaceutical compositions comprising, treating CFTR-mediated diseases such as cystic fibrosis, reducing its severity, or treating it symptomatically, methods of administration, and kits thereof . |